Insights
The first substantive action received during prosecution of a U.S. patent application is often a restriction requirement, in which the examiner determines that a single application claims two or more independent or distinct inventions that should be examined separately. Restriction requirements are routine, but the choices they trigger can shape the value of an entire patent family for years to come.
Because the USPTO imposes that split, 35 U.S.C. § 121 provides a safe harbor against double patenting. In general, patents issuing from applications separated as a result of a restriction requirement cannot be used as double-patenting references against one another, provided the statutory and judicial requirements are satisfied. In other words, an applicant who divides its claims because the USPTO required it should not be penalized for doing so.
After a restriction, the applicant elects one group of claims to prosecute in the original application. The nonelected groups are typically pursued in one or more divisional applications in the event that the applicant cancels claims in the nonelected group or the examiner does not rejoin claims in the nonelected group upon allowance of claims in the elected group. Continuation applications are another option that may also be filed to pursue broader or different claims that were not subject to the restriction.
Practitioners tend to focus on which group to elect first and which claims go into which later application. But an equally important question is: Which types of continuing applications should be filed, and in what order?
The answer can have significant consequences for obviousness-type double patenting (ODP), patent term, and whether the § 121 safe harbor remains available.
Consider four practical points:
If you want § 121 protection, the application pursuing the nonelected invention should be filed and designated as a divisional of the restricted application. A continuation or continuation-in-part (CIP) filed directly from the restricted parent generally will not qualify, and redesignating the application as a divisional after patent issuance will not cure the problem. See Pfizer v. Teva; Amgen v. Hoffmann-La Roche; In re Janssen Biotech.
The safe harbor applies only if the claims preserve the boundaries between the inventions identified by the examiner, a requirement the courts call “consonance.”
Consonance must be maintained across the relevant applications and patents, including the challenged patent, the reference patent, and the original restricted application. Claims that cross the boundaries established by the restriction requirement can defeat consonance and jeopardize safe-harbor protection, even where the applications otherwise have the appropriate divisional lineage. See St. Jude Medical v. Access Closure; Boehringer Ingelheim v. Barr.
A restriction requirement in the parent does not automatically provide safe-harbor protection throughout the patent family. In particular, a continuation filed directly from the restricted parent may create double-patenting complications for subsequently filed applications. See Bristol-Myers Squibb v. Pharmachemie.
A potentially better strategy is to establish the appropriate divisional lineage before filing continuations directed to the restricted invention.
In Amgen v. Hoffmann-La Roche, the Federal Circuit recognized that § 121 protection can extend to patents descending from a divisional, including through intervening continuations, but not to patents descending exclusively through continuations.
A continuation of a properly filed divisional may therefore qualify for the safe harbor, provided its claims remain consonant with the original restriction. By contrast, a continuation filed directly from the restricted parent cannot claim that protection merely because it pursues claims that could have been presented in a divisional.
Likewise, Boehringer Ingelheim v. Barr recognized that the safe harbor can extend to a divisional of a divisional. Thus, the original restriction requirement can support protection through a chain of continuing applications, provided the statutory requirements and consonance are maintained.
Under Allergan v. MSN Laboratories, a first-filed, first-issued patent cannot be invalidated for ODP based on a later-filed, later-issued, earlier-expiring patent sharing the same priority date. This makes the filing and issuance sequence particularly important when different family members receive different amounts of patent term adjustment (PTA).
Later applications may be more exposed. Under In re Cellect, ODP is assessed based on patent expiration dates after PTA has been added, potentially placing valuable additional patent term at risk.
For a later application expected to receive significant PTA, a properly filed divisional that maintains consonance may provide critical protection against an ODP rejection that would otherwise require a terminal disclaimer.
When responding to a restriction requirement, plan the entire anticipated patent family, not just the next application. Likewise, before filing each continuing application, ask:
Should it be filed and designated as a divisional? The § 121 safe harbor is tied to a qualifying divisional lineage, and redesignation after issuance will not cure an improper filing history.
Do the claims maintain consonance? Are the boundaries established by the original restriction requirement, including any applicable species election, preserved throughout the relevant applications?
Are continuations being filed from a divisional rather than directly from the restricted parent? Could the filing sequence affect the availability of the safe harbor for later patents?
Which applications are likely to receive PTA? Will the filing structure allow that additional patent term to be preserved without a terminal disclaimer?
The decision to file a continuation or divisional is more than an administrative designation. It can determine whether patents issuing years later retain the benefit of the § 121 safe harbor and, potentially, valuable patent term adjustment.
A little planning at the first restriction requirement can make a substantial difference in the long-term value of the patent family.
This article is for general information only and is not legal advice.
Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc., 518 F.3d 1353 (Fed. Cir. 2008).
In re Janssen Biotech, Inc., 880 F.3d 1315 (Fed. Cir. 2018).
Amgen Inc. v. Hoffmann-La Roche Ltd., 580 F.3d 1340 (Fed. Cir. 2009).
Boehringer Ingelheim Int’l GmbH v. Barr Laboratories, Inc., 592 F.3d 1340 (Fed. Cir. 2010).
St. Jude Medical, Inc. v. Access Closure, Inc., 729 F.3d 1369 (Fed. Cir. 2013).
Bristol-Myers Squibb Co. v. Pharmachemie BV, 361 F.3d 1343 (Fed. Cir. 2004).
In re Cellect, LLC, 81 F.4th 1216 (Fed. Cir. 2023).
Allergan USA, Inc. v. MSN Laboratories Private Ltd., 111 F.4th 1358 (Fed. Cir. 2024).
See also MPEP §§ 804.01 and 804.04.